First to 50: Early Outcomes Following Heart Transplantation at Royal Papworth Hospital from Donation after Circulatory Determined Death (DCD) Donors

Messer, Simon; Page, A.; Berman, Marius; Colah, Simon; Dunning, John; Pavlushkov, E.; Kaul, Pratibha; Parameshwar, Jayan; Abu‐Omar, Yasir; Pettit, Stephen; Lewis, Clive J.; Kydd, Anna; Bhagra, Sai; Cockell, A.; Quigley, R.; Baxter, Jennifer; Ellis, Charles D.; Jenkins, David P.; Sudarshan, Catherine; Ali, Ayyaz; Catarino, Pedro; Large, Stephen

doi:10.1016/j.healun.2019.01.090

Cited by 22 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With DP-ESP, the heart is inspected visually for evaluation, whereas NRP-ESP allows for additional cardiac assessment including echocardiography. These techniques for DCD heart procurement have been reported to have similar 30-day survival outcomes as compared to the hearts procured from brain dead donors [67].…”

Section: Dcd Donor Heart Procurementmentioning

confidence: 94%

New Approaches to Donor Selection and Preparation in Heart Transplantation

Tong

Khush

2021

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Purpose of review With increasing survival of patients with stage D heart failure, the demand for heart transplantation has increased. The supply of donor hearts remains relatively limited. Strategies have been investigated and new technologies have been developed to expand the current donor pool. These new approaches will be discussed herein. Recent findings Donor hearts are often considered "marginal" due to risk factors such as older age, size mismatch with the intended recipient, prolonged ischemic time, presence of left ventricular hypertrophy, and hepatitis B/C infection. We reviewed recent data regarding the use of donor hearts with these risk factors and suggest ways to safely liberalize current donor heart acceptance criteria. New technologies such as temperaturecontrolled transport systems and ex vivo cardiac perfusion methods have also demonstrated promising short-term and intermediate outcomes as compared with routine cold storage, by promoting heart preservation and enabling heart procurement from remote sites with shorter cold ischemic time. Recent use of hearts from donation after circulatory death donors has demonstrated comparable outcomes to conventional donation after brain death, which can further expand the current donor pool. Summary Careful selection of "marginal" donor hearts, use of ex vivo cardiac perfusion, and acceptance of hearts after circulatory death may expand our current cardiac donor pool with comparable outcomes to conventional donor selection and preparation methods.

show abstract

Section: Dcd Donor Heart Procurementmentioning

confidence: 94%

New Approaches to Donor Selection and Preparation in Heart Transplantation

Tong

Khush

2021

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

show abstract

“…The availability of clinically approved anti-IL1R and anti-TNFa antibodies (Anakinra, Swedish Orphan Biovitrum AB, Stockholm, Sweden and Etanercept, AMGEN, Thousand Oaks, CA, USA) make these avenues especially enticing. Heart IRIM via normothermic ex vivo perfusion has clinical approval and is currently available (319)(320)(321)(322). On the horizon for cardiac allotransplantation is hypothermic ex vivo perfusion.…”

Section: Heartmentioning

confidence: 99%

Minimizing Ischemia Reperfusion Injury in Xenotransplantation

et al. 2021

View full text Add to dashboard Cite

The recent dramatic advances in preventing “initial xenograft dysfunction” in pig-to-non-human primate heart transplantation achieved by minimizing ischemia suggests that ischemia reperfusion injury (IRI) plays an important role in cardiac xenotransplantation. Here we review the molecular, cellular, and immune mechanisms that characterize IRI and associated “primary graft dysfunction” in allotransplantation and consider how they correspond with “xeno-associated” injury mechanisms. Based on this analysis, we describe potential genetic modifications as well as novel technical strategies that may minimize IRI for heart and other organ xenografts and which could facilitate safe and effective clinical xenotransplantation.

show abstract

“…DCD heart transplants were then reported from two centers in England, Papworth and Harefield, also with good initial results (Messer et al 2017). The most recent reports from these centers show 2-year survival surpassing standard criteria brain dead donor transplants (Messer et al 2019). This raises the question of whether there may be additional benefits to DCD donors beyond just the expansion of the donor numbers.…”

Section: Donation After Cardiac Determination Of Deathmentioning

confidence: 99%